Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABBR2 | O75899 | 2/20 | 0.32 |
| ▸ | GABBR1 | Q9UBS5 | 2/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.32 |
| ▸ | LAP3 | P28838 | 2/20 | 0.32 |
| ▸ | FDPS | P14324 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4623205 | 0.75 | — | — | |
| SCHEMBL30905984 | 0.73 | GABBR2 (0.43) | GABBR2GABBR1GABRR1 | |
| SCHEMBL146464 | 0.73 | GABBR2 (0.43) | GABBR2GABBR1GABRR1 | |
| SCHEMBL5897538 | 0.71 | LMNA (0.41) | GABBR2GABBR1CYP2C19LMNAGABRR1 | |
| SCHEMBL5897242 | 0.71 | LAP3 (0.35) | GABBR2GABBR1CYP2C19LMNAGABRR1 | |
| SCHEMBL15067644 | 0.71 | GABBR2 (0.42) | GABBR2GABBR1GABRR1 | |
| SCHEMBL1766195 | 0.71 | GABBR2 (0.42) | GABBR2GABBR1GABRR1 | |
| SCHEMBL31206251 | 0.71 | GABBR2 (0.42) | GABBR2GABBR1GABRR1 | |
| SCHEMBL28378466 | 0.71 | GABBR2 (0.42) | GABBR2GABBR1GABRR1 | |
| SCHEMBL9982942 | 0.71 | GABBR2 (0.42) | GABBR2GABBR1GABRR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7005533-B2 | Bisphosphonate derivatives, their preparations and uses | UNIVERSITE PARIS 13 (FR) | 2006-02-28 | — | — | US | disclosed |
| US-20040266735-A1 | Bisphosphonate derivatives, their preparations and uses | UNIVERSITE PARIS 13 | 2004-12-30 | — | — | US | disclosed |
| US-20030036537-A1 | Bisphosphonate derivatives, their preparations and uses | UNIVERSITE PARIS, 13 (FR) | 2003-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030036537-A1 | Bisphosphonate derivatives, their preparations and uses | BPGM, PPIP5K2, PTEN | GABBR2 823/4885GABBR1 1307/4885CYP2C19 793/4885 |
| US-20040266735-A1 | Bisphosphonate derivatives, their preparations and uses | BPGM, PPIP5K2, PTEN | GABBR2 823/4885GABBR1 1307/4885CYP2C19 793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.